Skip to main content

Table 9 Co-expression of LAG-3 and IC PD-L1 in the molecular subtypes of breast cancer

From: Characterization of immune checkpoints expression and lymphocyte densities of iranian breast cancer patients; the co-expression status and clinicopathological associates

 

Negative (n = 183)

Positive (n = 84)

OR (95%CI)

P-value

Luminal A

80 (43.7)

16 (19.0)

1 (Reference)

0.001

Luminal B

62 (33.9)

42 (50.0)

3.38 (1.74, 6.58)

< 0.001

HER2-enriched

21 (11.5)

8 (9.5)

1.90 (0.71, 5.05)

0.195

TNBC

20 (10.9)

18 (21.4)

4.50 (1.95, 10.34)

< 0.001

  1. PD-L1, programmed death-ligand 1; IC, immune cell; LAG-3, lymphocyte activation gene-3; OR, odds ratio; CI, confidence interval; HER2, human epidermal growth factor receptor 2; TNBC, triple-negative breast cancer.4
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us